New drug tested for Tough-to-Treat prostate cancer
NCT ID NCT01171898
Summary
This study tested the safety and initial effectiveness of an experimental drug called ARN-509 in men with advanced prostate cancer that had progressed despite standard hormone therapy. The first part of the study aimed to find a safe dose, and the second part tested that dose in different groups of patients. Researchers measured how well the drug controlled cancer markers and delayed disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
San Diego, California, United States
-
Study site
San Francisco, California, United States
-
Study site
Atlanta, Georgia, United States
-
Study site
Baltimore, Maryland, United States
-
Study site
Boston, Massachusetts, United States
-
Study site
Ann Arbor, Michigan, United States
-
Study site
Omaha, Nebraska, United States
-
Study site
New York, New York, United States
-
Study site
Raleigh, North Carolina, United States
-
Study site
Portland, Oregon, United States
-
Study site
Lancaster, Pennsylvania, United States
-
Study site
Myrtle Beach, South Carolina, United States
-
Study site
Dallas, Texas, United States
-
Study site
Seattle, Washington, United States
-
Study site
Madison, Wisconsin, United States
Conditions
Explore the condition pages connected to this study.